Furthest ahead in the pipeline is tolebrutinib, developed by Paris-based Sanofi to potentially treat SPMS, PPMS and relapsing forms of MS. The investigational agent is an oral central nervous system ...
GlobalData on MSN1d
Nurix Therapeutics’ NX-5948 shows promise in Waldenstrom’s macroglobulinaemia trialUS-based biopharmaceutical company Nurix Therapeutics has reported positive clinical data from its ongoing Phase Ia/Ib trial ...
During a Case-Based Roundtable® event, Andrew H. Lipsky, MD, moderated a discussion on the efficacy and safety of newer BTK ...
In the years since targeted treatments for CLL were introduced, their use in the second line has increased, but chemotherapy ...
Shandong New Time Pharmaceutical Co. Ltd. has disclosed compounds acting as Bruton tyrosine kinase (BTK) inhibitors reported to be useful for the treatment of cancer and autoimmune diseases.
Exscientia plc (Nasdaq: EXAI) today announced three abstracts to be presented at the 36th EORTC-NCI-AACR (ENA) Symposium 2024 ...
A comparison of the second-generation Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to the first-generation ibrutinib ...
Schrödinger's stock has fallen 64% since January 2023, driven by missed revenue and EPS targets. Read why I maintain my hold ...
The study found that the price tag for the second-generation Bruton tyrosine kinase inhibitor would need to be reduced by 30% ...
BeiGene has seven presentations at IWWM 2024, and Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at ...
Presentations will summarize new preclinical data from brain-penetrant, pan-mutant B-Raf degrader program and recent clinical data from NX-5948 ...
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback